Thus, the benefits of valsartan and amlodipine in lipolysis may be through PU.1 inhibition in fructose-induced adiposity, and PU.1 inhibition might have a potential therapeutic role in lipolysis in fructose-induced obesity. The gene discussed is SPI1; the disease is obesity due to melanocortin 4 receptor deficiency.